The estimated Net Worth of Road Llc Summer is at least $72.5 Milion dollars as of 26 February 2024. Road Summer owns over 930,851 units of Ocular Therapeutix Inc stock worth over $72,511,424 and over the last 5 years Road sold OCUL stock worth over $0.
Road has made over 17 trades of the Ocular Therapeutix Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Road bought 930,851 units of OCUL stock worth $7,000,000 on 26 February 2024.
The largest trade Road's ever made was buying 1,538,461 units of Ocular Therapeutix Inc stock on 14 December 2023 worth over $4,999,998. On average, Road trades about 281,565 units every 85 days since 2020. As of 26 February 2024 Road still owns at least 8,591,401 units of Ocular Therapeutix Inc stock.
You can see the complete history of Road Summer stock trades at the bottom of the page.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer a Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: